Related references
Note: Only part of the references are listed.Global patterns and trends in colorectal cancer incidence and mortality
Melina Arnold et al.
GUT (2017)
EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
Yasuyuki Okada et al.
MOLECULAR CANCER RESEARCH (2017)
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
Shinji Kohsaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
Cristiana Lo Nigro et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients
Martino Monteverde et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab
Jeonghee Cho et al.
MOLECULAR CANCER (2014)
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
Sandra Misale et al.
CANCER DISCOVERY (2014)
Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization
Jeonghee Cho et al.
CANCER RESEARCH (2013)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
Differential Sensitivity of Glioma-versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors
Igor Vivanco et al.
CANCER DISCOVERY (2012)
Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies
Jeonghee Cho et al.
CANCER RESEARCH (2011)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab:: A fluorescent in situ hybridization study
Nicola Personeni et al.
CLINICAL CANCER RESEARCH (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
H Greulich et al.
PLOS MEDICINE (2005)
Epidermal growth factor independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression
JR Jiang et al.
CANCER RESEARCH (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Share Paper
